Immunic Inc. (IMUX) PT Raised to $61 at BMO Capital, Following Drug Trial Results
Tweet
Share
E-mailGet Alerts IMUX Hot Sheet
Price: $15.36 +3.36%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 82
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 82
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intercontinental Exchange (ICE) PT Lowered to $190 at UBS Following June Metrics Release
- Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal
- AppLovin Corp (APP) PT Raised to $575 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
